Results 191 to 200 of about 161,793 (289)

Molecularly targeted therapy and immunotherapy in leukemias. [PDF]

J Hematol Oncol
Cousin E, Picard A, Oundjian M, Tardif N, Quemener A, Rio AG, Galibert MD, Gandemer V, Mazurier F.   +8 more
europepmc   +1 more source

Clinical Outcomes and Prognostic Factors in AML with Hyperleukocytosis: A Multicenter Real-World Study

Ebru KILIC GUNES
openalex   +1 more source

Outcomes among non‐Western immigrant patients and Danish‐born patients with acute myeloid Leukaemia: A Danish population‐based cohort study

British Journal of Haematology, EarlyView.
Summary Non‐Western immigrant patients (NWIPs) may be a vulnerable population when diagnosed and treated for acute myeloid leukaemia (AML). Here we report selected quality parameters related to diagnosis, treatment, and outcome of newly diagnosed AML among NWIPs (n = 119) and Danish‐born patients (DBPs) (n = 4689). No adjusted differences were observed
Daniel Tuyet Kristensen, Mikkel Runason Simonsen, Anne Stidsholt Roug, Claus Werenberg Marcher, Andreas Due Ørskov, Anne Louise Tøllbøll Sørensen, Tarec Christoffer El‐Galaly, Joachim Baech   +7 more
wiley   +1 more source

Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine. [PDF]

Cancer
Buchrits S, Rozental A, Korngold N, Algor O, Partouche S, Granot G, Raanani P, Wolach O.   +7 more
europepmc   +1 more source

Long-term Success of Prophylactic Intrathecal Therapy in AML Patients with CNS Involvement: Two Cases with Extended Remission Following Stem Cell Transplantation

Birol Güvenç
openalex   +1 more source

Deoxycytidine kinase expression in AML blasts and its relationship to leukemia-free and overall survival

, 2017
Lui Ng, C.K. Chan, Trang H. Au, Eric C. K. Cheng, Ke Mo, W. Li, Lei Kou, Tony Mok, Margaret H.L. Ng, Radha Raghupathy   +9 more
openalex   +1 more source

Genocopy of EVI1‐AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking

British Journal of Haematology, EarlyView.
Summary Diabetes insipidus (DI) in patients with acute myeloid leukaemia (AML) and chromosome 3q alterations (EVI1/PRDM3/MECOM overexpression) constitutes a poorly understood paraneoplasia. A 44‐year‐old patient presented with clinical and morphological features of this syndrome but, surprisingly, disclosed the rare translocation t(1;2)(p36;p21), with ...
Julian List, Etienne Sollier, Fiona Brown‐Burke, Katherine Kelly, Dietmar Pfeifer, Valeria Shlyakhto, Kristina Maas‐Bauer, Milena Pantic, Christoph Plass, Michael Lübbert   +9 more
wiley   +1 more source

Regulatory role of mTORC1 signaling in osteoblasts in acute myeloid leukemia progression and steady-state hematopoiesis. [PDF]

iScience
Fukasawa K, Tokumura K, Yoshimoto M, Sadamori K, Mosialou I, Harakawa Y, Isawa K, Tsuji S, Inufusa H, Hirao A, Kousteni S, Hinoi E.   +11 more
europepmc   +1 more source

Global Patterns, Temporal Trends, and Potential Non-Infectious Risk Factors for Burkitt Lymphoma from 1990 to 2021. [PDF]

Blood Lymphat Cancer
Jin SK, Lyu JT, Feng ZY, Zhang SQ, Lu BY, Yan QF, Li J, Du J, Huang ZF.   +8 more
europepmc   +1 more source

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O. Ciurea, Jorge Ramos‐Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi   +11 more
wiley   +1 more source